Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Singh, N.
Right arrow Articles by Light, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Singh, N.
Right arrow Articles by Light, R.

Chest, Vol 103, 800-804, Copyright © 1993 by American College of Chest Physicians

ARTICLES

Effects of buspirone on anxiety levels and exercise tolerance in patients with chronic airflow obstruction and mild anxiety

NP Singh, JA Despars, DW Stansbury, K Avalos and RW Light
Department of Medicine, Veterans Administration Medical Center, Long Beach, Calif. 90822.

The objective of this study was to determine if buspirone would alleviate anxiety and improve exercise tolerance of anxious patients with chronic airflow obstruction (CAO). Eleven male patients with mild to moderate anxiety and CAO completed this study comparing buspirone, 10 to 20 mg given three times a day, with placebo. Patients were evaluated with State Trait Anxiety Inventory, spirometry, 12-min walk, incremental exercise on a cycle ergometer to symptom limitation and measurement of dyspnea with a modified Borg scale at exercise levels and the end of each 2 min on 12-min walk. There were no significant differences in anxiety scores, work load, maximum oxygen consumption per minute, maximum expired volume per minute, PETCO2, PETO2, 12-min walking distance or dyspnea scores after 6 weeks of buspirone or placebo therapy. We conclude that administration of buspirone has no significant effect on anxiety levels, exercise capabilities or PETO2 or PETCO2 in patients with CAO and mild anxiety.


This article has been cited by other articles:


Home page
 ChestHome page
A. S.Y. Leung, K. K. Chan, K. Sykes, and K. S. Chan
Reliability, Validity, and Responsiveness of a 2-Min Walk Test To Assess Exercise Capacity of COPD Patients.
Chest, July 1, 2006; 130(1): 119 - 125.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. Juan, M. Ramon, J. C. Valia, J. Cortijo, E. Rubio, E. Morcillo, and P. Calverley
Palliative Treatment of Dyspnea With Epidural Methadone in Advanced Emphysema
Chest, November 1, 2005; 128(5): 3322 - 3328.
[Abstract] [Full Text] [PDF]

Home page
 PsychosomaticsHome page
J. W. Smoller, M. H. Pollack, D. Systrom, and R. L. Kradin
Sertraline Effects on Dyspnea in Patients With Obstructive Airways Disease
Psychosomatics, February 1, 1998; 39(1): 24 - 29.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by the American College of Chest Physicians.